ENDACE 40 MG

The defining feature of Megestrol acetate is its progestational agent activity. Synthetic progestin with hormonal and appetite-stimulating effects. The therapeutic effect is tied to estrogen or other hormone signaling, so receptor status, menopausal context, and disease setting help define its place in treatment. Within this database it is listed under Hormonal / Endocrine Therapy; Progestin. The principal indications are Selected endometrial and breast cancers; cancer-associated anorexia/cachexia symptom management, with Endometrial; Breast; supportive oncology identified as the associated tumor types. Its treatment role can differ substantially between these settings, so the disease context matters as much as the drug class. Regimens listed for the medicine include Hormonal therapy; appetite-supportive care protocols. The database places it within endocrine management, where the hormonal environment and disease state are important determinants of clinical use. Where a molecular alteration, receptor status, or prior-treatment requirement appears in the indication, that criterion is part of the clinical context rather than an optional detail. The medicine may consequently occupy an induction, maintenance, adjuvant, metastatic, salvage, or supportive position depending on the setting recorded here. The summary is descriptive and does not provide individualized dosing or administration instructions. Current product information and disease-specific guidance should be checked before clinical application.